Daily Brief Health Care: Amgen Inc, Regeneron Pharmaceuticals, Sionna Therapeutics and more

In today’s briefing:

Amgen: How Its $3.5 Billion Acquisition & Its High-Stakes Drug Pipeline Are Reshaping Its Growth Strategy
Regeneron Pharmaceuticals: Libtayo Expansion To Up Their Oncology Game!
Sionna Therapeutics Inc. (SION): RA Capital Backed Biotech IPO Booms in Debut

Amgen: How Its $3.5 Billion Acquisition & Its High-Stakes Drug Pipeline Are Reshaping Its Growth Strategy

Amgen Inc. highlighted substantial achievements and growth potential for 2024 while outlining some challenges and strategies moving forward.
The company’s financial results reflected its success across various therapeutic areas, despite facing pricing pressures and patent expirations.
Revenue for the full year of 2024 reached $33.4 billion, reflecting a significant 19% increase year-over-year, driven mainly by a 23% volume increase across products.

Regeneron Pharmaceuticals presented its fourth-quarter 2024 results, revealing a 10% year-over-year revenue growth, driven by strong performances from key product lines such as Dupixent, EYLEA, and Libtayo.
Dupixent, in particular, has become a blockbuster treatment in multiple indications, showing robust uptake across the globe with more than 1 million patients currently benefiting from the drug in various approved applications.
However, the performance of EYLEA was noted in a competitive landscape, with the company focused on increasing the market share of EYLEA HD through upcoming product enhancements like prefilled syringe options and extended dosing intervals.

Biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis opened its IPO 39% above issue.
The transaction was upsized from 8.8mm shares to 10.6mm shares and priced at the high-end of the range.
The IPOs that are more apt to see “follow-through” in the aftermarket are those with product candidates in later stage. This IPO does not meet that criteria.

💡 Before it’s here, it’s on Smartkarma

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network